Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI

Purpose The aim of this study is to evaluate the impact of weight loss at presentation on treatment outcomes of first-line EGFR-tyrosine kinase inhibitors (EGFR-TKI) in EGFR-TKI sensitive mutant NSCLC patients.Methods We retrospectively analyzed the clinical outcomes of 75 consecutive advanced NSCLC patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R) received first-line gefitinib or erlotinib therapy according to weight loss status at presentation in our single center.Results Of 75 EGFR-TKI sensitive mutant NSCLC patients, 49 (65.3%) patients had no weight loss and 26 (34.7%) had weight loss at presentation, the objective response rate (ORR) to EGFR-TKI treatment were similar between the two groups (79.6% vs. 76.9%, p = 0.533). Patients without weight loss at presentation had significantly longer median progression free survival (PFS) (12.4 months vs. 7.6 months; hazard ratio [HR] 0.356, 95% confidence interval [CI] 0.212-0.596, p
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

Publication date: Available online 17 July 2019Source: Biomedicine &PharmacotherapyAuthor(s): Mao-Chi Weng, Ming-Hsin Li, Jing Gung Chung, Yu-Chang Liu, Wu Jeng-Yuan, Fei-Ting Hsu, Hsin-Ell Wang
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionThe presence of co-mutations was lower in the EGFR mutation patients and reduces the efficacy of EGFR-TKI, especially in patients with distant metastases. Lower frequency of co-mutation in PIK3CA and PI3K/AKT/mTOR pathway genes may be responsible for promoting metastasis and limiting the efficacy of EGFR-TKIs.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aims to assess the prognostic significance of the qualification for BEV use and the proportion of patients who potentially benefit from BEV-containing combination therapy before and after initial EGFR-TKI treatment.MethodsWe retrospectively analyzed the data of 297 patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) harboringEGFR mutations who had received EGFR-TKIs. We performed statistical analyses using the Kaplan –Meier method and the Cox regression adjusted for risk factors.ResultsOf the 297 patients, 203 (68%) were eligible to receive BEV ( “BEV fit”) at th...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
In the ph 3 PACIFIC study of unresectable, Stage III NSCLC pts without progression after chemoradiotherapy (CRT), durvalumab (durva) demonstrated significant improvements versus placebo (pbo) in the primary endpoints progression-free survival and overall survival, with manageable safety and no detrimental effect on pt-reported outcomes. We performed exploratory analyses to characterize patterns of disease progression, including the sites of first progression.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
WEDNESDAY, Sept. 18, 2019 -- For patients with non-small cell lung cancer (NSCLC), responders and nonresponders can be differentiated by a metal oxide semiconductor electronic nose (eNose) analysis of exhaled breath before starting antiprogrammed...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsDecrease in the rates of perioperative outcomes parallels improvements in patient selection and perioperative management of early-stage NSCLC resection patients. Predictors of pulmonary complication could be used to improve selection criteria for surgery and to reduce the incidence of pulmonary complication in these patients.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
AbstractObjectivesThe aim of this study is to evaluate the surgical results of clinical N1 disease and to clarify the high-risk clinical N1 subgroup.MethodsBetween 1990 and 2012, 137 patients who were clinically diagnosed as having N1 disease were enrolled. Their medical records were reviewed to assess clinical characteristics, radiologic findings, pathologic results, postoperative outcomes, recurrence patterns, and survival. Logistic regression analysis was used to identify independent predictive factors for pathologic N2 upstaging. To determine which factors were significantly associated with survival, a multivariate ana...
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Streptomyces-derived natural products have been become a major focus of anti-tumor drug discovery studies. Neoantimycin F (NAT-F), was isolated from Streptomyces conglobatus by our group. Here, we examined the anti-cancer activities and its underlying molecular mechanisms implicated in NAT-F–induced apoptosis of non–small cell lung cancer (NSCLC) cells. Our results showed that NAT-F exerted excellent growth-inhibitory activity against PC9 and H1299 cells in a concentration-dependent manner. NAT-F–induced cell cycle arrest at S and G0/G1 phase in PC9 and H1299 cells, respectively. Further investigation rev...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Patient Outcome Assessment;   Morbidity;   Mortality Intervention:   Procedure: Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy Sponsor:   AHEPA University Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Biological: Durvalumab;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Pemetre...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva | Weight Loss